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ABSTRACT 
Tuberculosis is one of the serious airborne infectious diseases. Rifampicin is commonly used as anti-tuberculosis drug which creates drug-
induced hepatotoxicity. Physiologically, liver maintains metabolic homeostasis and also regulates the detoxification process.  The study of 
rifampicin mediated hepatotoxicity had been performed on male albino rat after its oral administration with a dose of 50 mg/kg body 
weight/day for 14 days. Several biochemical markers like serum glutamate pyruvate tranaminase (AST), serum glutamate oxaloacetate 
transaminase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), serum total protein, serum bilirubin, serum cholesterol were 
considered to evaluate the toxicity. Significant elevation of level of AST (115.89%), ALT (134.40%), ALP (46.15%), serum cholesterol (91%) and 
bilirubin content (119.44%) had been observed in treated group compared with control group. High level of MDA content as lipi d peroxidation 
marker was also been noticed in drug induced group. Histopathological studies had shown the disintegrated hepatolobular structure with 
dilated central vein. All these findings indicated that the selected dose of rifampicin is hepatotoxic; proper monitoring and care are essential 
during the treatment of tuberculosis.  
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Abbreviations 
ABCB1: ABC transporter subfamily B member 1; ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspertate transaminase; CP: 
continuation phase; DILI: drug-induced liver injury; HRZE: isoniazid, rifampicin (RIF), pyrazinamide, and ethambutol; IP: intensive Phase; LDH: 
lactate dehydrogenase; LPO: lipid peroxidation; MDA: malondialdehyde; PPAR: proliferators activated receptor gamma; PXR: pregnane X 
receptor; RIF: rifampicin; ROS: reactive oxygen species:  
INTRODUCTION  
Liver is the “metabolic factory” of the body and plays central 
role to control the metabolism of every nutrient as well as 
foreign substances including drugs. Hepatic cytochrome P-
450 enzyme system is essential for biotransformation of 
drugs through oxidative pathways followed by conjugation 
with glucuronide/sulphate/glutathione which convert the 
molecules to hydrophilic metabolites those are excreted by 
the kidney or through the gastrointestinal tract.1 Owing to 
these properties, liver is the main target of drug toxicity and 
drug-induced liver injury (DILI) is the most common side 
effect in clinical.2 Currently, over 1000 drugs are known to 
cause DILI, and the list is continuously growing up.3 Zhou et 
al.4 reported that anti-tuberculosis drugs were the leading 
agents of DILI. Tuberculosis is one of the top curable 
infectious diseases and creates serious public health 
problem in developing countries. According to World Health 
Organization, 9.6 million people were suffering from 
tuberculosis and 1.5 million had been died in 2014.5 In 
developed countries, the incidence of tuberculosis increases 
due to immunodeficiency disease like HIV (human 
immunodeficiency virus) infection.6 Currently, four major 
pharmacological agents (isoniazid, rifampicin, pyrazinamide, 
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and ethambutol) are used as anti-tuberculosis drug. The 
regimen for adult respiratory tuberculosis treatment 
includes a combined preparation of isoniazid, rifampicin 
(RIF), pyrazinamide, and ethambutol (HRZE; H=75mg / 
R=150mg / Z=400mg / E=275mg) for 2 months as Intensive 
Phase (IP) of treatment, followed by additional four months 
of Continuation Phase (CP) of treatment with HRE (H=75mg 
/ R=150 mg / E=275 mg).7 Among these drugs, rifampicin 
(RIF) is the main initiator of hepatotoxicity.8 It causes 
hepatocellular dysfunction followed by hepatic lesions, 
cellular changes, lobular necrosis and  hyperbilirubinemia.9  
Sensi et al.10 had isolated rifamycin from the culture of 
Streptomyces mediterranei which is the derivative [3-(4-
methyl-1-piperazinyl)-iminomethyl] of rifamycin. 
Rifampicin is a complex semisynthetic macrocyclic 
antibiotic11 with empirical formula C43H58N4O12 and molar 
mass 822.953 g/mol. This polyketide compound belongs to 
ansamycins class of molecule containing 
napthoquinone core in the heterocyclic structure that is 
spanned by an aliphatic ansa chain. The 
napthoquinonic chromophore gives red-orange crystalline 
colour of rifampicin. This drug is well absorbed from the 
stomach and then metabolized in the liver by deacetylation 
followed by hydrolysis to give 3-formyl rifampicin. Deacetyl 
rifampicin is more polar than the parent compound, and 
microbiologically active.12, 13 Rifampicin binds to the β 
subunit of RNA polymerase through hydrogen 
bonds between hydroxyl groups of the ansa bridge and the 
napthol ring containing amino acid residues of RNA 
polymerase.14 The outcome is inhibition of bacterial DNA-
dependent RNA synthesis.  
.In the present scenario, multi-drug therapy is the best 
choice for the treatment of tuberculosis instead of isoniazid 
mono-drug therapy. However, hepatotoxicity is one of the 
serious problems, especially for RIF. The present study has 
primarily focused on the mechanism of RIF-induced liver 
injury in rat model.  
MATERIAL AND METHODS 
Chemicals 
Sodium chloride (NaCl), Potassium dihydrogen phosphate 
(KH2PO4), Dipotassium hydrogen phosphate (K2HPO4), 
Sodium hydroxide (NaOH), Trichloro acetic acid (TCA), 
Thiobarbituric acid (TBA), Potassium hydroxide (KOH), 
Alcohol, and other chemicals had been procured from Merck 
Ltd., SRL Pvt. Ltd., Mumbai, India and rifampicin had been 
purchased from HiMedia Laboratories, Pvt. Ltd., Mumbai, 
India.  
Selection of animals and maintenance 
The study was performed on 18 healthy Wister strain male 
albino rats, having a body weight of 100 ± 15 g, supplied by 
Saha Enterprise, Kolkata (CPSEA, Govt. of India registered 
farm). They were acclimatized in laboratory condition for a 
period of 2 weeks. Proper care for the experimental animals 
was provided according to the guidelines of the “Committee 
for the Purpose of Control and Supervision of Experiments 
on Animals (CPCSEA)”, India and all experimental 
procedures were approved by Institutional Animal Ethical 
Committee (Reg No. 1617/GO/Re//S/12/CPCSEA). 
Experimental animals were housed (three rats per cage) in a 
room having temperature 22 ± 2 °C, humidity 50 ± 10% with 
12 ± 1 h light and 12 ± 1 h dark cycle. To carry out the 
experiments, the experimental animals were divided into 
three groups and each group comprises 6 rats (n=6/gr). 
Group-I (control group) received normal diet and water ad 
libitum, Group-II (rifampicin induced treated group) 
received normal diet, water ad libitum and oral 
supplementation of rifampicin with a dose of 50 mg/kg body 
weight/day15 for 14 days, and Group-III (Sham treated 
group) received normal diet, water ad libitum and oral 
supplementation of riboflavin with a dose of 10 mg/kg body 
weight/day as placebo. Previously, riboflavin was also used 
as placebo by Low et al.16  
Sacrifice of animals and collection of blood and tissues  
Over the treatment schedule of 14 days, body weight of all 
the experimental animals were taken by using animal’s 
weighing machine. Then, the animals were sacrificed (as per 
guideline of CPSEA, Govt. of India) to evaluate the rifampicin 
mediated hepatoxicity. Blood sample was collected from the 
aorta, and hepatic tissue was taken for different biochemical 
and histological studies. Before preservation of hepatic 
tissue, the weight of liver of all three groups was recorded. 
The tissues were stored into −20 °C until preparation of 
tissue homogenates. For histological examination, liver was 
preserved in 10% neutral formaldehyde solution till 
processed.  
Histological study 
Hepatic tissue was washed in ethanol for dehydration and 
the portion of the tissue was embedded in paraffin wax. 
Histological slides were made by cutting the section in 6 μm 
thickness. Eosin and hematoxylin stain were used to observe 
the histo-architecture of the hepatic tissue. The 
histopathological changes were recorded by using scoring 
system.  
Separation of serum and preparation of liver homogenate 
Serum was separated by centrifugation (1500×g for 15 min) 
of blood samples and then kept in –20 °C for biochemical 
estimation of different parameters. Similar type method was 
also followed by Tripathy et al.17 Tissue homogenate was 
prepared through the following process: 1.5 g hepatic tissue 
was washed initially in 0.9% normal saline and made 
homogenate in ice-cold buffer (0.25 M sucrose, 1 mM EDTA, 
and 1 mM Tris-HCl, pH 7.4). The homogenate was 
centrifuged at 6000×g for 10 min in 4 °C.18 Then supernatant 
was separated and stored at –20 ⁰C for biochemical study.  
Study of biochemical markers of hepatotoxicity 
The extent of hepatotoxicity was determined by measuring 
the activities of several important intracellular hepatic 
enzymes like aspartate transaminase (AST), alanine 
transaminase (ALT), alkaline phosphatase (ALP), lactate 
dehydrogenase (LDH) in serum and tissue homogenate. 
Serum bilirubin, total protein and albumin concentration 
were also estimated. All these assays were performed by 
using assay kits of Span Diagnostics Ltd., India. 
Assessment of lipid peroxidation  
The degree of lipid peroxidation (LPO) in tissue homogenate 
was measured by estimating the formation of thiobarbituric 
acid reactive substances (TBARS) as malondialdehyde 
(MDA) content according to the method of Ohkawa et al.19 
The reaction mixture contained tissue homogenate (200 µl) 
20% TCA (1.5 ml) and 1.34% TBA (1.5 ml) mixture followed 
by boiling for 30 minutes, then allowed to cool by addition of 
2.5 ml butanol. The whole mixture was centrifuged at 
2000×g for 5 minutes and then optical density of 
supernatants was measured at 535 nm. The amount of 
malondialdehyde (MDA) content was expressed as nmol of 
MDA/mg of protein. 
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RESULTS  
Measurement of body weight and liver weight 
The alterations of body weight and liver weight were 
measured and the results were furnished in Table 1. The rate 
of increase of mean body weight was very slow in treated 
group compared to control group and sham treated group. 
The liver weight had proportionately increased in control 
group and sham treated group along with body weight. 
While, the treated animals showed minimum increase of 
liver weight; this might be accumulation of lipid. 
  
Table 1. Effect of rifampicin on body weight and liver weigh. 
Group Body weight (gm) Liver weight (gm) 
0 days 7 days 14 days 14 days 
Control 125.5  2.33 132.0  2.58 138.5  2.67 6.4  0.93 
Treated 122.5  3.9 123.7  4.1 129.0  1.98 * 5.2  0.53* 
Sham treated 124.22  2.83 136.0  4.58 139.6  1.67 6.2  0.72 
Values are expressed as Mean  SEM, n=6; * indicates significant difference (P < 0.001) 
compared to control Group. 
 
Biochemical markers of hepatotoxicity 
In this present study, hepatotoxicity was started after 
administration of rifampicin (50 mg/kg body wt/rat/day). 
The mean value of serum AST, ALT, ALP, LDH, of hepatic 
tissue had been increased significantly (p < 0.001) by 
115.89%, 134.40%, 46.15% and 173.94%, respectively in 
rifampicin treated Group compared to control group (Fig. 1); 
but, any significant changes did not observed in placebo 
receiving Group. However, the activities of these enzymes in 
hepatic tissue homogenate were decreased by 26.47%, 
41.55%, 7.65% and 25.38% respectively in treated group.  
The activity of these enzymes in sham treated group was 
very nearer to the control group (Fig. 1). The total protein 
and albumin content in serum were decreased significantly 
(p < 0.001) by 36.11% and 53.38% respectively in 
rifampicin treated group in respect of control group. 
Albumin-globulin ratio (A/G) had been dropped to 50% of 
its original value after treatment (Table 2). An insignificant 
change in protein concentration had been found in sham 
treated group. Beside these, the serum cholesterol level 
significantly increased upto 91.0% in the treated group. 
Administration of rifampicin showed a significant (P < 
0.001) elevation of serum bilirubin (total, conjugated and 
unconjugated) by 119.40%, 47.82% and 148.0% 
respectively (Table 3). In this study, MDA content was 
measured to evaluate the lipid peroxidation and degree of 
membrane damage. MDA content was significantly 
(P<0.001) increased by 194.0% in treated group compared 
to control group (Fig. 2). However, no such significant 
changes were observed in sham treated group. 
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Figure 1. Graphical presentation represents the effect of rifampicin on AST (A), ALT (B), ALP (C) and LDH (D) activity in 
control, treated and sham treated animals. Values are expressed as mean ± SEM, n =6. * indicates significant difference (P < 
0.001) compared to control Group.  
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Table 2. Effect of rifampicin on serum total protein, albumin and albumin-
globulin ratio. 
Group Serum total protein 
(mg/dl) 
Serum albumin 
(mg/dl) 
Albumin-
globulin ratio 
Control 9.22  1.14 4.72  0.86 1.04 
Treated 5.89  0.6* 2.2  0.35* 0.56 
Sham treated 8.56  0.98 4.82  0.86 1.28 
Values are expressed as Mean  SEM, n=6; * indicates significant difference (P < 0.001) 
compared to control Group. 
 
Table 3. Effect of rifampicin on serum cholesterol and bilirubin. 
Group Serum cholesterol 
(mg/dl) 
Serum bilirubin (mg/dl) 
Total Cojugated Unconjugated 
Control 72.17  4.12 0.36  0.014 0.115  0.007 0.25  0.016 
Treated 138.2  3.57* 0.79  0.038* 0.17  0.005 0.62  0041* 
Sham treated 73.57  3.47 0.34  0.016 0.120  0.005 0.27  0.019 
Values are expressed as Mean  SEM, n=6; * indicates significant difference (P < 0.001) compared to 
control Group. 
 
 
Figure 2. Graphical presentation represents the effect of 
rifampicin on MDA content in control, treated and sham 
treated animals. Values are expressed as mean ± SEM, n =6. * 
indicates significant difference (P < 0.001) compared to 
control Group.  
Histological examinations 
Marked changes had been found in rifampicin treated group 
compared to control group and placebo supplemented sham 
treated group. The, histological study of the liver sections of 
control animals showed normal hepatocellular architecture 
without any sign of necrosis along with well preserved 
hepato-lobular pattern and normal size of central vein. These 
findings were also very similar in sham treated group. 
However, liver sections of rifampicin treated group had 
shown the lipid accumulation, massive cellular necrosis, 
enlargement of central vein and sinusoidal space, and portal 
vein disruption which indicates loss of cellular architecture 
due to excessive intracellular lipid deposition (Fig. 3 Table 
4). 
 
Normal Treated Sham treated  
Figure 3. Histological structure of liver of Control, rifampicin and Sham treated group. The sections were stained by eosin and 
hematoxylin and observed under 40 magnification. 
Table 4. Histological changes in liver. The scoring was made in six-point scale according to 
Ishak et al. 1995.36 
Parameters  Control group Rifampicin treated 
group 
Sham treated 
group 
Cellular necrosis 0 5 0 
Hepatocyte degeneration 0 5 1 
Portal vein disruption 2 4 2 
Lipid Accumulation 0 5 0 
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DISCUSSION 
Drug induced liver injury is very common during the 
treatment of tuberculosis. The rate of DILI is approximately 
58% and 5–22% cases has been linked to acute liver 
failure.20 In the treatment regimen of tuberculosis, RIF is the 
first-line drug, but exerts sever hepatototoxicity after its 
administration.21 The present study indicated that all the 
toxicity related marker enzymes like ALT, AST. ALP and LDH 
(Fig. 1) increased significantly in serum of treated animals. 
The leaching of the intracellular enzymes occurred due to 
oxidative stress induced LPO mediated membrane damage. 
Similar type findings were also reported by Rana et al.15 and 
Kim et al.9 A scheme of proposed mechanism of rifampicin 
induced liver injury has been given in Figure 4 which 
indicates that hepatotoxicity is directly associated to 
cytochorome P450 dependent drug metabolism. Rifampicin 
is an agonist of xeno sensing pregnane X receptor (PXR) 
which is a member of nuclear receptor superfamily of ligand 
dependent transcription factors.13 RIF induces the over 
expression of pregnane X receptor (PXR); the result is more 
amount of CYP3A4 subset of cytochorome P450 enzyme, 
responsible for drugs/xenobiotics metabolism.22 The PXR 
mediated inducible enzymes, are CYP2B6, 2C9, 2C19, and 
3A4. PXR also increases the transcriptional activity of ATP 
dependent ABCB1 transporter. Beside these, PXR regulates 
the metabolism of bile acid, bilirubin, steroid hormone, 
glucose and lipid.23 Decreased value of serum total protein 
and albumin (Table 2) are very common during any type of 
hepatoxicity. Generally, liver is the site for synthesis of most 
of the plasma proteins except gamma globulin and any 
injury/toxicity of the hepatocytes reduces the rate of 
formation of plasma proteins. 
Rifampicin had tended to increases the lipid peroxidation 
marker such as MDA (Fig. 2) which is associated with 
oxidative stress (OS). Chowdhury et al.24 reported that RIF 
stimulates oxidative stress (OS) mediated lipid peroxidation 
(LPO) in hepatic cells. Oxidative stress promotes excess 
production of ROS (O2, OH, H2O2) which starts LPO 
mediated membrane damage. ROS binds with unsaturated 
units of the polyunsaturated fatty acids of membrane lipids. 
This reaction converts the membrane lipids (RH) to lipid 
macro radical (ROO) in presence of oxygen and promotes 
continuation of the chain reactions of lipid peroxidation. 
Finally, ROO was modified to hydroperoxide (ROOH) or 
endoperoxide followed by malondialdehyde.18 Accumulation 
of MDA indicates the imbalance of redox homeostasis as well 
as tissue damage. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Proposed hypothetical model of mechanism of rifampicin induced liver injury. 
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The significant increase of serum total bilirubin (both 
conjugated and unconjugated) was observed after 
administration of RIF (Table 3). Jussi et al.25 reported that 
RIF hampered the bilirubin uptake; the result is subclinical 
unconjugated hyperbilirubinemia. Conjugated 
hyperbilirubinemia was due to inhibition of the bile salt 
exporter pump.26 Moreover, improper bilirubin clearance at 
the sinusoidal membrane or impeded secretion at the 
canalicular level may also enhance the serum bilirubin 
level.27, 28. 
The results of histological studies of rifampicin treated 
group had revealed that there were marled changes in 
cellular disintegration, lipid accumulation, alteration of 
cytoarchitecture and necrosis of the hepatic cells (Fig. 3) 
along with significant elevation of serum cholesterol level 
(Table 3). Previously, it was reported that RIF mediated liver 
damage is done by increasing oxidative stress in 
mitochondria, apoptotic response of liver cell, cholestasis 
effects, and hepatic lipid accumulation in rodent.21 The 
accumulation of lipid in hepatic cells is made via up-
regulation of peroxisome proliferators activated receptor 
gamma (PPAR). Recently, Kim et al.9 had observed that up-
regulation of PPAR stimulates the expression of five proteins 
(apolipoprotein C-III, acyl-CoA-binding protein, 3-ketoacyl-
CoA thiolase A and B, and perilipin-2) related to lipid 
metabolism. Actually, perilipin coats the lipid droplets in 
adipocytes with phospholipid monolayer and maintains the 
maturation and metabolism of lipid droplets.29, 30 The 
coating of perilipin suppresses lipolysis and promotes 
accumulation of lipid droplets in hepatic tissue.31, 32  
The overall findings indicated that rifampicin mediated 
hepatotoxicty was a complex process. The multi-drug 
(isoniazid, RIF, pyrazinamide, and ethambutol) therapy 
against tuberculosis enhances the potential effects of 
hepatotoxic.33 RIF induces the activity of CYP3A4 which 
leads to increases the metabolism of isoniazid, yielding toxic 
metabolites like isonicotinic acid and hydrazine by activating 
isoniazid hydrolases.34, 35 At the later stage, hydrazine is 
further metabolized to more toxic components such as N-
hydroxy acetyl hydrazine, acetyl diazine, acetyl onium ion, 
acetyl radical.13 Thus, RIF amplifies the hepatotoxic effects of 
anti-tuberculosis drugs.  
CONCLUSION 
In conclusion, it can be stated that anti-tuberculosis drug, 
rifampicin alters the level of serum protein, serum bilirubin, 
MDA content, AST, ALT, ALP and LDH enzymes activity in 
albino rat when orally administered for 14 consecutive days. 
Till now, except these drugs there are no alternative 
medicines for the treatment of tuberculosis. Thus, proper 
monitoring and care must be given during the period of 
treatment of tuberculosis. 
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